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Conclusion: This retrospective study shows that the 
SUVmax50 pre-therapeutic signal correlates with the post-
therapeutic recurrences in the majority of patients. Pre-
therapeutic PET/CT or planning PET/CT is a useful tool to 
guide the future dose escalation studies. 
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Purpose or Objective: 
Background: There is great potential to utilise a large range 
of retrospective clinical data as an evidence base in decision 
support systems (DSS) for cancer prognosis and subsequent 
personalised treatment decisions. Recently, there were 
several DSSs built for this purpose using machine learning 
tools, mainly regression models, Bayesian Networks (BN) and 
Support Vector Machines (SVM). These machine learning tools 
provide only a prediction of a class (decision), based on input 
attributes that were used to build the model, without 
providing additional information to clinicians about how and 
why this prediction was made. 
Objective: To investigate the performance of an alternative 
machine learning tool in building a lung cancer radiotherapy 
DSS that provides clinicians with an estimated prediction 
together with the influencing attributes and their values 
(evidence) in supporting the decision reached. This will 
provide contextual justification to clinicians regarding the 
decisions, which will further help them in deciding whether 
to adopt the machine prediction or not. 
 
Material and Methods: A Non-Small Cell Lung Cancer 2 year 
survival prediction model was built, using data at Liverpool 
Cancer Therapy Centre in NSW, Australia. The attributes used 
to predict the survival were age, gender, ECOG, GTV and 
FEV1. The machine learning tool used is a Decision Tree 
which automatically extracts rules from the training data and 
formulates these as if-then-else patterns. A report of the 
used rules during the prediction process indicates the 
effective attributes used to reach the decision. SVM, 
Regression models and BN were built and tested using the 
same data set; however, BN possess less, and SVM/Regression 
models possess none, of this reporting capability as they are 
learned by analysing probabilities and numerical distances 
among data points associated with prediction class. 
 
Results: The DSS was learnt within the Liverpool Clinic with 
an unfiltered cohort of 4650 4686 patients. After filtering out 
patient records with missing values for the used attributes 
the cohort was reduced to 97 patients treated radically. The 
area under curve of the Decision Tree, SVM, Regression Model 
and BN when tested using a rigorous 10 fold cross-validation 
method respectively was 0.62, 0.62, 0.63 and 0.6. There is no 
significant difference in the performance between the four 
tools examined, however, the decision tree also generates an 
understandable context with every prediction made as a list 
of supporting attributes like the example in Figure 1. 
 
 
 
Conclusion: It is possible to build a DSS for NSCLC data that 
provides a prediction with additional information justifying 
the decision with similar performance as the commonly 
utilised SVM, BN and regression tools. To improve the 
performance and avoid over fitting, more diverse and 
complete training data is needed by incorporating data from 
other centres to the learning process using distributed 
learning. 
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Purpose or Objective: Stereotactic body radiotherapy (SBRT) 
is an attractive modality for the definitive treatment of 
oligometastatic or unresectable primary lung malignancies. 
Proximity of the tumor to adjacent organs-at-risk (OAR) may 
limit delivery of a sufficiently ablative dose. The ability to 
adapt to tumor response during treatment may improve OAR 
sparing and/or allow dose escalation. This study aimed to 
evaluate the degree of daily interfractional variation in gross 
tumor volume (GTV) during SBRT for patients with 
oligometastatic or unresectable primary malignancy of the 
central thorax using a magnetic resonance image guided 
radiotherapy (MR-IGRT) treatment system. 
 
Material and Methods: Eleven patients with unresectable 
primary or oligometastatic malignancy of the central thorax 
were treated at our institution with extended fractionation 
SBRT on a clinical MR-IGRT system. Treatment regimens 
consisted of 60 Gy in 12 fractions (n=8) or 62.5 Gy in 10 
fractions (n=3). For each treatment fraction, low-field (0.35 
Tesla) MR setup imaging was acquired as part of routine 
clinical practice. Daily GTV was retrospectively defined on 
MR image sets for all patients at each of 10 or 12 fractions, 
using initial GTVs from CT simulation as a template. Daily 
tumor volumes were then recorded and compared for each 
patient to evaluate for interfractional change in tumor 
volume. 
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Results: All patients demonstrated on-treatment reduction in 
MRI-defined GTV (Figure 1). Average reduction in tumor size 
from treatment initiation to completion of therapy was 51.0% 
(median 52.1%) and ranged from 30.5-70.8%. At a time point 
of fraction six, average reduction in GTV size was 38.2% 
(median 34.8%). Linear correlation across median values at 
each time point suggested a consistent decline over time of 
approximately 4% per day, with the most pronounced changes 
occurring between the 5th and 6th fractions. 
 
 
 
Conclusion: Tumor volume decreased considerably during 
treatment for most patients undergoing lung SBRT. The 
dosimetric impact of this degree of MRI-defined tumor 
volume change during the course of therapy has yet to be 
assessed. However, adaptive planning during the course of 
SBRT may be dosimetrically advantageous for sparing of 
surrounding critical structures, particularly for disease 
involving the central thorax. 
 
EP-1226  
Quality of life in locally-advanced non-small cell lung 
cancer patients: a systematic review 
L. Van der Weijst
1Ghent University Hospital, Radiation Oncology, Ghent, 
Belgium 
1,2, W. Schrauwen3, V. Surmont4,5, Y. 
Lievens1,2 
2Ghent University, Radiation Oncology, Ghent, Belgium 
3Ghent University Hospital, Medical Oncology, Ghent, 
Belgium 
4Ghent University Hospital, Respiratory Medicine, Ghent, 
Belgium 
5Ghent university, Respiratory Medicine, Ghent, Belgium 
 
Purpose or Objective: Non-small cell lung cancer has a 
substantial impact on health-related quality of life (HRQoL) 
of affected patients. Measuring HRQoL in lung cancer 
patients is an important approach to forecast and assess the 
relative risks and benefits of a treatment as experienced by 
patients. A systematic literature review was performed to 
provide an overview of prospective studies measuring HRQoL 
in patients with locally-advanced non-small lung cancer (LA-
NSCLC) receiving treatment with curative intent, published 
over the last 10 years.  
 
Material and Methods: The literature search was performed 
in four electronic databases: PubMed, ScienceDirect, 
MEDLINE and Embase. The inclusion criteria for the studies 
were: English language, clinical trial, study population with 
LA-NSCLC, treatment with curative intent, HRQoL 
assessment, full text availability and published over the last 
10 years.  
 
Results: Only 5 studies out of the 225 potentially eligible 
studies matched our inclusion criteria. Four of these were 
randomized controlled trials; one was a prospective cohort 
study. All studies included radiotherapy at least in one of the 
evaluated treatment arms. Details of the studies and the 
analyzed parameters are shown in the table. HRQoL was a 
secondary endpoint in four studies and a co-primary endpoint 
in one. No significant treatment-related improvement or 
deterioration in HRQoL has been reported in the included 
studies. Variability has been observed in terms of use of 
HRQoL instruments and statistical analysis.  
 
Conclusion: Evaluation of HRQoL in patients with LA-NSCLC 
receiving curative intent treatment remains scarce. 
Reporting and statistical analysis of HRQoL data lacks 
standardization. More research is needed to address these 
issues in both clinical trials and daily care of patients 
receiving radiotherapy as part of their primary treatment for 
LA-NSCLC. Based on these considerations, a prospective 
cohort study has been launched in our institute, which aims 
to evaluate HRQoL, treatment-induced toxicity and 
neurocognitive functioning in patients with unresectable LA-
NSCLC receiving radiotherapy, all or not in combination with 
concurrent or sequential chemotherapy.  
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Purpose or Objective: To evaluate clinical outcomes of 
salvage radiotherapy for regional lymph node (LN) recurrence 
developing after radical surgery of non-small cell lung cancer 
(NSCLC). 
 
Material and Methods: Between 2008 and 2013, out of 
patients with NSCLC who achieved complete response (CR) 
after definitive treatment (surgery with or without 
chemotherapy), 31 patients developed regional LN 
(mediastinum, hilum, and supraclavicular area) recurrence 
(median age, 66 years; stage Ⅰ, n = 17; stage Ⅱ, n = 7; stage 
ⅢA, n = 7). The median time from definitive surgery to 
recurrence was 12 months (range, 3-80). Fifteen patients 
(48.4%) had single LN recurrence and others had multiple LN 
recurrence. All patients were irradiated to the recurred LN 
area with daily fractions of 2.0 Gy (n = 27), 2.5 Gy (n = 2), or 
3.0 Gy (n = 2) by 3D-conformal radiotherapy. The median 
total dose for recurred LN was 66 Gy (BED 79.2 Gy10; range, 
65.1-79.2 Gy10). Sixteen patients received chemotherapy 
either. 
 
Results: The median follow-up was 14 months (range, 3-76). 
After salvage radiotherapy, 16 patients (51.6%) achieved CR, 
9 patients (29.0%) partial response, and 6 patients (19.4%) 
stable disease. After salvage radiotherapy, one- and two-year 
in-field local control rate was 88.4% and 75.8%, respectively. 
Only two patients experienced an out-of-field mediastinal 
recurrence. One- and two-year progression-free survival rate 
from initial salvage radiotherapy was 73.1% and 50.9%, 
respectively. Progression site was predominantly distant. 
Overall, ten of 31 patients (32.3%) were successfully salvaged 
as CR state. Recurred LN size (<3 vs. ≥3 cm) was a significant 
prognostic factor for progression-free survival (p = 0.03). 
Pneumonitis requiring conservative treatment (grade 2 or 
more) occurred in 5 patients (16.1%). There was no radiation-
related mortality. 
 
Conclusion: Salvage radiotherapy for regional LN recurrence 
after radical surgery was suggested to be an effective 
treatment option with an acceptable level of toxicity. The 
recurred node size (3 cm cutoff value) was a strong predictor 
of progression-free survival. Aggressive salvage radiotherapy 
should be considered as a front-line treatment in regional LN 
recurrence of NSCLC. 
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